Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Radiopharm Theranostics Limited Sponsored ADR ( (RADX) ) is now available.
Radiopharm Theranostics Limited announced its upcoming Annual General Meeting (AGM) scheduled for November 20, 2025, which will be held both physically in Victoria, Australia, and virtually via the Automic Investor Portal. The meeting will cover ordinary business such as the consideration of financial statements, re-election of directors, and the ratification of prior share placements. The AGM will also address special business, including the approval of equity securities issuance under the Omnibus Incentive Plan. This meeting is significant for stakeholders as it involves key decisions on corporate governance and strategic financial moves, potentially impacting the company’s future growth and shareholder value.
The most recent analyst rating on (RADX) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited Sponsored ADR stock, see the RADX Stock Forecast page.
More about Radiopharm Theranostics Limited Sponsored ADR
Radiopharm Theranostics Limited operates in the medical technology industry, focusing on the development and commercialization of radiopharmaceutical products. The company is based in Australia and is involved in providing innovative solutions for the detection and treatment of various diseases.
Average Trading Volume: 34,678
Technical Sentiment Signal: Strong Buy
Current Market Cap: $41.41M
Find detailed analytics on RADX stock on TipRanks’ Stock Analysis page.